Last reviewed · How we verify
Prevenar and Meningitec
These are conjugate vaccines that stimulate the immune system to produce antibodies against specific bacterial pathogens by linking polysaccharide antigens to protein carriers.
These are conjugate vaccines that stimulate the immune system to produce antibodies against specific bacterial pathogens by linking polysaccharide antigens to protein carriers. Used for Prevention of invasive pneumococcal disease caused by 13 serotypes of Streptococcus pneumoniae (Prevenar), Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C (Meningitec).
At a glance
| Generic name | Prevenar and Meningitec |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Drug class | Conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide capsule (Prevenar); Neisseria meningitidis serogroup C polysaccharide capsule (Meningitec) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Prevenar is a pneumococcal conjugate vaccine targeting 13 serotypes of Streptococcus pneumoniae, while Meningitec is a meningococcal conjugate vaccine targeting serogroup C. Both work by conjugating bacterial polysaccharide capsules to diphtheria toxoid or other protein carriers, enabling T-cell dependent immune responses that generate long-lasting antibody protection against invasive bacterial disease.
Approved indications
- Prevention of invasive pneumococcal disease caused by 13 serotypes of Streptococcus pneumoniae (Prevenar)
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C (Meningitec)
Common side effects
- Injection site erythema, swelling, or pain
- Fever
- Irritability or fussiness
- Myalgia or fatigue
Key clinical trials
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (PHASE3)
- Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine (PHASE2)
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines (PHASE2)
- Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines (PHASE3)
- Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevenar and Meningitec CI brief — competitive landscape report
- Prevenar and Meningitec updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI